Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
XAIR
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q1.23
N/A
-0.67
vs -0.26
Q2.23
N/A
-0.45
vs -0.37
Q3.23
N/A
-0.51
vs -0.40
Q4.23
N/A
-0.50
vs -0.43
Q1.24
N/A
-0.36
vs -0.67
Q2.24
N/A
-0.27
vs -0.45
Q3.24
N/A
-0.28
vs -0.51
Q4.24
N/A
-0.15
vs -0.50
Q1.25
N/A
-0.12
vs -0.36
Q2.25
N/A
-0.10
vs -0.27
Sales Growth
YoY
Current
Estimates
Q1.23
NA
NA vs NA
Q2.23
NA
59K vs NA
Q3.23
NA
239K vs NA
Q4.23
NA
391K vs NA
Q1.24
NA
470K vs NA
Q2.24
+1058%
683K vs 59K
Q3.24
+234%
798K vs 239K
Q4.24
+174%
1.1M vs 391K
Q1.25
+193%
1.4M vs 470K
Q2.25
+201%
2.1M vs 683K
Return on Equity
QoQ
Q1.23
-53%
-0.53
vs -0.25
Q2.23
-40%
-0.40
vs -0.53
Q3.23
-63%
-0.63
vs -0.40
Q4.23
-78%
-0.78
vs -0.63
Q1.24
-55%
-0.55
vs -0.78
Q2.24
-76%
-0.76
vs -0.55
Q3.24
-47%
-0.47
vs -0.76
Q4.24
-74%
-0.74
vs -0.47
Institutionnal Ownership
QoQ
Q1.23
61
61
vs 57
7%
Q2.23
69
69
vs 61
13%
Q3.23
67
67
vs 69
-3%
Q4.23
67
67
vs 67
NA
Q1.24
71
71
vs 67
6%
Q2.24
65
65
vs 71
-8%
Q3.24
46
46
vs 65
-29%
Q4.24
47
47
vs 46
2%
Quote Panel
Key Metrics
globenewswire.com
8 hours ago
globenewswire.com
16 hours ago
globenewswire.com
16 hours ago
globenewswire.com
16 hours ago
Forecast
265%2025-Revenue
-395%2025-EPS
93%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
0.00(-100.00%)
Number of analyst
0
Last analyst upgrade/downgrade
BTIG
downgradePrevious: Buy
2024-06-25
Now: Neutral
BTIG
downgradePrevious: Buy
2024-06-25
Now: Reduce
Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
0.01 ( 4.78%)
Relative Strenght
3
Volume Buzz
-59%
Earning Acce
No
Dist 52w H.
87%Relative Strength
XAIR
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|